Tamás Andrea, Zsombok Andrea, Farkas Orsolya, Reglödi Dóra, Pál József, Büki András, Lengvári István, Povlishock John T, Dóczi Tamás
Department of Anatomy (Neurohumoral Regulations Research Group of the Hungarian Academy of Sciences), University of Pécs, Medical Faculty, Pécs, Hungary.
J Neurotrauma. 2006 May;23(5):686-95. doi: 10.1089/neu.2006.23.686.
Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system. Numerous studies have shown its neuroprotective effects both in vitro and in vivo. Previously, it has been demonstrated that PACAP reduces brain damage in rat models of global and focal cerebral ischemia. Based on the protective effects of PACAP in cerebral ischemia and the presence of common pathogenic mechanisms in cerebral ischemia and traumatic brain injury (TBI), the aim of the present study was to investigate the possible protective effect of PACAP administered 30 min or 1 h postinjury in a rat model of diffuse axonal injury. Adult Wistar male rats were subjected to impact acceleration, and PACAP was administered intracerebroventricularly 30 min (n = 4), and 1 h after the injury (n = 5). Control animals received the same volume of vehicle at both time-points (n = 5). Two hours after the injury, brains were processed for immunohistochemical localization of damaged axonal profiles displaying either beta-amyloid precursor protein (beta-APP) or RMO-14 immunoreactivity, both considered markers of specific features of traumatic axonal injury. Our results show that treatment with PACAP (100 microg) 30 min or 1 h after the induction of TBI resulted in a significant reduction of the density of beta-APP-immunopositive axon profiles in the corticospinal tract (CSpT). There was no significant difference between the density of beta-APP-immunopositive axons in the medial longitudinal fascicle (MLF). PACAP treatment did not result in significantly different number of RMO-14-immunopositive axonal profiles in either brain areas 2 hours post-injury compared to normal animals. While the results of this study highlighted the complexity of the pathogenesis and manifestation of diffuse axonal injury, they also indicate that PACAP should be considered a potential therapeutic agent in TBI.
垂体腺苷酸环化酶激活多肽(PACAP)在神经系统中有多种不同作用。大量研究已表明其在体外和体内均具有神经保护作用。此前,已有研究证明PACAP可减轻全脑和局灶性脑缺血大鼠模型中的脑损伤。基于PACAP在脑缺血中的保护作用以及脑缺血和创伤性脑损伤(TBI)存在共同致病机制,本研究旨在探讨在弥漫性轴索损伤大鼠模型中,伤后30分钟或1小时给予PACAP可能的保护作用。成年雄性Wistar大鼠接受撞击加速损伤,分别于伤后30分钟(n = 4)和1小时(n = 5)经脑室内给予PACAP。对照组动物在两个时间点均接受相同体积的溶剂(n = 5)。伤后两小时,对大脑进行处理,以免疫组化定位显示β-淀粉样前体蛋白(β-APP)或RMO-14免疫反应性的受损轴突轮廓,这两种均被视为创伤性轴索损伤特定特征的标志物。我们的结果显示,在TBI诱导后30分钟或1小时给予PACAP(100微克)可显著降低皮质脊髓束(CSpT)中β-APP免疫阳性轴突轮廓的密度。内侧纵束(MLF)中β-APP免疫阳性轴突的密度之间无显著差异。与正常动物相比,伤后两小时,PACAP治疗在两个脑区中RMO-14免疫阳性轴突轮廓的数量上均未产生显著差异。虽然本研究结果突出了弥漫性轴索损伤发病机制和表现的复杂性,但也表明PACAP应被视为TBI的一种潜在治疗药物。